Non–Small Cell Lung Cancer: Dual-Modality PET/CT in Preoperative Staging

PURPOSE: To determine the accuracy of dual-modality positron emission tomographic (PET)–computed tomographic (CT) imaging, as compared with PET alone and CT alone, in the staging of non–small cell lung cancer (NSCLC).

MATERIALS AND METHODS: Twenty-seven patients with NSCLC underwent staging with combined fluorine 18 fluorodeoxyglucose PET and CT. CT, PET, and coregistered PET/CT images were evaluated separately by two different physicians for each imaging modality, and disease stage was determined by using TNM and American Joint Committee on Cancer staging systems. Histopathologic results served as the reference standard. The statistical significance of differences among CT, PET, and PET/CT was determined by using the McNemar test.

RESULTS: Overall tumor stage was correctly classified as 0–IV with CT in 19 patients, with PET in 20 patients, and with PET/CT in 26 patients. PET/CT findings when compared with PET findings led to a treatment change for four patients (15%) and when compared with CT findings led to a treatment change for five patients (19%). Differences in the accuracy of overall tumor staging between PET/CT and CT (P = .008) and between PET/CT and PET (P = .031) were significant. Primary tumor stage was correctly determined in more patients with PET/CT than with either PET alone or CT alone. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of regional lymph node staging, respectively, were 89%, 94%, 89%, 94%, and 93%, with PET/CT; 89%, 89%, 80%, 94%, and 89% with PET; and 70%, 59%, 50%, 77%, and 63% with CT. Fourteen distant metastases were detected in four patients with CT, four were detected in two patients with PET, and 17 were detected in four patients with PET/CT.

CONCLUSION: Use of dual-modality PET/CT significantly increases the number of patients with correctly staged NSCLC and thus has a positive effect on treatment.

© RSNA, 2003


  • 1 Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47. Crossref, MedlineGoogle Scholar
  • 2 Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002; 122:1037-1057. Crossref, MedlineGoogle Scholar
  • 3 AJCC cancer staging manual 6th ed New York, NY: Springer, 2002; 165-177. Google Scholar
  • 4 Smythe WR. Treatment of stage I and II non-small cell lung cancer. Cancer Control 2001; 8:318-325. Crossref, MedlineGoogle Scholar
  • 5 Haura EB. Treatment of advanced non-small cell lung cancer: a review of current randomised clinical trials and an examination of emerging therapies. Cancer Control 2001; 8:326-336. Crossref, MedlineGoogle Scholar
  • 6 Barker JM, Silvestri GA. Lung cancer staging. Curr Opin Pulm Med 2002; 8:287-293. Crossref, MedlineGoogle Scholar
  • 7 Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (< 1 cm), intermediate (1 to 3 cm), and large (> 3 cm) lymph node lesions. Chest 2000; 117:773-778. Crossref, MedlineGoogle Scholar
  • 8 Marom EM, McAdams PH, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212:803-809. LinkGoogle Scholar
  • 9 Pieterman RM, van Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343:254-261. Crossref, MedlineGoogle Scholar
  • 10 Gupta NC, Graeber GM, Rogers JS, Bishop HA. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann Surg 1999; 229:286-291. Crossref, MedlineGoogle Scholar
  • 11 Weber WA, Avril N, Schwaiger M. Relevance of positron emission tomography (PET) in oncology. Strahlenther Onkol 1999; 175:356-373. Crossref, MedlineGoogle Scholar
  • 12 Townsend DW. A combined PET-CT scanner: the choices. J Nucl Med 2001; 42:533-534. MedlineGoogle Scholar
  • 13 Beyer T, Townsend DW, Brun T, et al. A combined PET-CT scanner for clinical oncology. J Nucl Med 2000; 41:1369-1379. MedlineGoogle Scholar
  • 14 Beyer T, Townsend DW, Blodgett TM. Dual-modality PET-CT tomography for clinical oncology. Q J Nucl Med 2002; 46:24-34. MedlineGoogle Scholar
  • 15 von Schulthess GK. Cost considerations regarding an integrated CT-PET system. Eur Radiol 2000; 10:S377-S380. Crossref, MedlineGoogle Scholar
  • 16 Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET-CT scanner. Med Phys 1998; 25:2046-2053. Crossref, MedlineGoogle Scholar
  • 17 Hawkins RA, Choi Y, Huang SC, et al. Quantitating tumor glucose metabolism with FDG and PET. J Nucl Med 1992; 33:339-344. MedlineGoogle Scholar
  • 18 Huang SC. Anatomy of SUV. Nucl Med Biol 2000; 27:643-646. Crossref, MedlineGoogle Scholar
  • 19 Antoch G, Egelhof T, Korfee S, Frings M, Forsting M, Bockisch A. Recurrent schwannoma: diagnosis with PET-CT. Neurology 2002; 59:1240. Crossref, MedlineGoogle Scholar
  • 20 Glazer GM, Gross BH, Quint LE, et al. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol 1985; 144:261-265. Crossref, MedlineGoogle Scholar
  • 21 Lowe VJ, DeLong DM, Hoffmann JM, et al. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995; 36:883-887. MedlineGoogle Scholar
  • 22 Deslauriers J, Gregoire J. Clinical and surgical staging of non-small cell lung cancer. Chest 2000; 117:96S-103S. Crossref, MedlineGoogle Scholar
  • 23 Stapels CA, Muller NL, Miller RR, et al. Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. Radiology 1988; 167:367-372. LinkGoogle Scholar
  • 24 Dwamena BA, Sonnad SS, Angobaldo JO, Wahl R. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s—meta-analytic comparison of PET and CT. Radiology 1999; 213:530-536. LinkGoogle Scholar
  • 25 Haag DW, Follette DM, Roberts PF, Shelton D, Segel LD, Taylor TM. Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer. J Surg Res 2002; 103:160-164. Crossref, MedlineGoogle Scholar
  • 26 Lee JD, Ginsberg RJ. Lung cancer staging: the value of ipsilateral scalene lymph node biopsy performed at mediastinoscopy. Ann Thorac Surg 1996; 62:338-341. Crossref, MedlineGoogle Scholar
  • 27 Weder W, Schmid RA, Bruchhaus H, Hillinger S, von Schulthess GK, Steinert HC. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998; 66:886-893. Crossref, MedlineGoogle Scholar
  • 28 Antoch G, Freudenberg LS, Stattaus J, et al. Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol 2002; 179:1555-1560. Crossref, MedlineGoogle Scholar
  • 29 Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions. JAMA 2001; 285:914-924. Crossref, MedlineGoogle Scholar

Article History

Published in print: Nov 2003